04:30 , Nov 30, 2018 |  BC Week In Review  |  Clinical News

RedHill's Yeliva yields one partial response in MM patient in preliminary Phase Ib data

RedHill Biopharma Ltd. (Tel Aviv:RDHL; NASDAQ:RDHL) said Yeliva opaganib (ABC294640) led to one very good partial response and two cases of stable disease lasting more than four months among 10 evaluable multiple myeloma patients in...
22:36 , Apr 4, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: March 2018

New Therapeutic Targets and Biomarkers: March 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during March 2018. Therapeutic targets are defined as any protein, gene or other...
23:10 , Mar 20, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer; autoimmune disease

INDICATION: Solid tumors; Crohn’s disease; inflammatory bowel disease (IBD) In vitro , cell culture and mouse studies suggest inhibiting CDK9 and GSK3 could help treat cancer, Crohn’s disease and ulcerative colitis. Chemical synthesis and in...
22:56 , Jan 5, 2018 |  BC Week In Review  |  Clinical News

RedHill starts Phase II trial of Yeliva for cholangiocarcinoma

RedHill Biopharma Ltd. (Tel Aviv:RDHL; NASDAQ:RDHL) began an open-label, U.S. Phase IIa trial of Yeliva (ABC294640) to treat cholangiocarcinoma. The study is expected to enroll up to 39 patients with advanced, unresectable intrahepatic, perihilar or...
02:03 , Jan 24, 2017 |  BC Week In Review  |  Clinical News

Yeliva: Ph Ib/II started

RedHill began an open-label, dose-escalation, U.S. Phase Ib/II trial to evaluate 250, 500 and 750 mg oral Yeliva twice daily in up to 77 patients who were previously treated with proteasome inhibitors and immunomodulatory drugs....
07:00 , Oct 17, 2016 |  BC Week In Review  |  Clinical News

Yeliva: Phase II started

RedHill began a U.S. Phase II trial to evaluate oral Yeliva in 39 patients who have received prior Nexavar sorafenib therapy. The company has exclusive, worldwide rights to Yeliva from Apogee (see BioCentury, April 27,...
07:00 , Sep 12, 2016 |  BC Week In Review  |  Clinical News

Yeliva: Phase Ib/II started

RedHill began an open-label, U.S. Phase Ib/II trial to evaluate oral Yeliva in patients who have previously been treated with proteasome inhibitors and immunomodulatory drugs. The Phase Ib portion will evaluate 250, 500 and 750...
07:00 , Jul 11, 2016 |  BC Week In Review  |  Clinical News

Yeliva: Phase I final data

Final data from 16 evaluable patients with advanced solid tumors in an open-label, U.S. Phase I trial showed that once-daily oral Yeliva led to 1 partial response and 6 cases of stable disease. The patient...
08:00 , Nov 2, 2015 |  BC Week In Review  |  Clinical News

Yeliva: Phase I data

Top-line data from an open-label, U.S. Phase I trial in 21 patients with advanced solid tumors showed that once-daily oral Yeliva was well tolerated with grade 1/2 fatigue and nausea reported as the most common...
07:00 , Sep 7, 2015 |  BC Week In Review  |  Clinical News

Apogee Biotechnology, RedHill preclinical data

In a xenograft model of prostate cancer, oral ABC294640 significantly inhibited tumor growth. Data were published in Molecular Cancer Research. RedHill is evaluating the small molecule inhibitor of sphingosine kinase 2 (SPHK2) in a Phase...